

1 **Global Assessment of IRF8 as a Novel Cancer Biomarker**

2

3 Daniel C. McQuaid BS<sup>1</sup>; Gauri Panse MD<sup>1</sup>; Wei-Lien Wang MD<sup>2</sup>;

4 Samuel G. Katz, MD, PhD<sup>1\*</sup>; Mina L. Xu, MD<sup>1\*</sup>

5

6 1 Department of Pathology, Yale New-Haven Hospital,  
7 Yale School of Medicine, New Haven, CT

8 2 Department of Pathology and Translational Molecular  
9 Pathology, University of Texas MD Anderson Cancer  
10 Center, Houston, TX

11 \* These authors contributed equally to this work

12

13 Conflict of interest: The authors have no conflicts of interest to disclose.

14 Running Title: IRF8 IHC detects hematopoietic tumors

15 Keywords: Myeloid sarcoma, blastic plasmacytoid dendritic neoplasms, IRF8, cancer tissue  
16 microarrays

17

18 Corresponding authors:

19 Samuel G. Katz  
20 Email: [samuel.katz@yale.edu](mailto:samuel.katz@yale.edu)  
21 Phone: 203-785-2757  
22 Fax: 203-785-3583  
23 310 Cedar Street, LH315B  
24 New Haven, CT 06510

25 Mina L. Xu  
26 Email: [mina.xu@yale.edu](mailto:mina.xu@yale.edu)  
27 Phone: 203-737-6135  
28 Fax: 203-785-6135  
29 310 Cedar Street, BML116  
30 New Haven, CT 06510

31 **Abstract**

32 Interferon regulatory factor 8 (IRF8) is a member of the IRF family that is specific to the  
33 hematopoietic cell and is involved in regulating the development of human monocytic and  
34 dendritic-lineage cells, as well as B cells. Since its utility as a sensitive and specific monoblast  
35 marker in the context of acute monocytic leukemias has been recently demonstrated, we  
36 hypothesized that it may also be useful as a novel immunohistochemical marker in myeloid  
37 sarcomas and blastic plasmacytoid dendritic cell neoplasms (BPDCN) with respect to their  
38 differential diagnoses. In this retrospective study, we analyzed the IHC expression pattern of  
39 IRF8 in 385 patient samples across 30 types of cancers, referenced to their mRNA expression  
40 data available through TCGA. In addition, we assessed IRF8 in 35 myeloid sarcomas, and 13  
41 BPDCNs. Twenty-four of 35 cases of myeloid sarcomas (68.5%) showed positivity for IRF8, with  
42 six cases (17.1%) demonstrating IRF8 expression in the absence of CD34 and MPO. All 13 of 13  
43 BPDCNs (100%) showed strong uniform expression of IRF8 and was occasionally more definitive  
44 than CD123. IRF8 was negative in all desmoplastic small round cell tumors, Ewing sarcomas,  
45 synovial sarcomas, and undifferentiated pleomorphic sarcomas, as well as all epithelial  
46 malignancies tested except for 2 triple negative breast cancers that showed subset weak  
47 staining. In conclusion, IRF8 is a novel marker helpful in identifying extranodal hematopoietic  
48 tumors that can otherwise be difficult to diagnose given the broad differential diagnoses and  
49 frequent loss of more common lineage-defining markers.

50

51

52

## 53 **1.0: Introduction**

54 Interferon regulatory factor 8 (IRF8) is a hematopoietic-specific member of the IRF family that is  
55 essential in the commitment of myeloid progenitors to monocyte, macrophage, and dendritic  
56 cell lineages (1, 2). IRF8 expression is significantly elevated in monocyte-dendritic cell  
57 progenitors in mice and conversely, *Irf8*<sup>-/-</sup> mice lack bone marrow resident macrophages,  
58 dendritic cells, and plasmacytoid dendritic cells in lymphatic tissue (3-5). The role of IRF8 in the  
59 generation of monocyte and dendritic cell progenitors is conserved in humans, as mutations  
60 that impair IRF8 transcriptional activity are associated with immunodeficiency via decreased  
61 monocyte and dendritic cell populations (6). Past work has shown that IRF8 is upregulated in  
62 subsets of acute myeloid leukemia (AML) and correlates with poor prognosis in AML patients  
63 (7). Moreover, we recently demonstrated that IRF8 immunohistochemistry stains monoblasts in  
64 cases of acute monocytic leukemia and advanced chronic myelomonocytic leukemia, but is  
65 negative in mature monocytes and granulocytes (8). Given this observation, IRF8 may hold  
66 promise as a biomarker for additional malignancies derived from early monocyte and dendritic  
67 cell precursors.

68  
69 Myeloid sarcoma is a less common hematologic malignancy of immature monocyte and/or  
70 granulocyte populations that manifests as an extramedullary soft tissue mass (9). It is defined  
71 by the World Health Organization as a tumor of myeloid blasts that occurs at an anatomic  
72 location beyond the bone marrow (10). Myeloid sarcoma typically develops secondary to AML,  
73 although rare cases of isolated disease without bone marrow involvement or history of myeloid  
74 malignancy have been described (11). These tumors most commonly arise at the lymph nodes,

75 skin, soft tissues, and bone, and must cause effacement of local tissue in order to render a  
76 myeloid sarcoma diagnosis (10). Due to the disparate sites of disease involvement, clinical  
77 presentation is varied and pathology evaluation is critical for diagnosis. However, myeloid  
78 sarcoma is notoriously difficult to diagnose, with an estimated misdiagnosis rate of 25-47% (12-  
79 14). This diagnostic inaccuracy is a product of disease rarity, particularly in the absence of a  
80 known myeloid disorder, as well as a dearth of markers for staining (15). Histologically, the  
81 tumor demonstrates myeloid cell infiltration with myeloblasts or monoblasts (16). Of note,  
82 lesions with granulocytic differentiation have features such as eosinophilic metamyelocytes  
83 that aid in a myeloid sarcoma diagnosis, while tumors of monocytic origin lack these  
84 characteristics and are typically more difficult to diagnose (12). Consequently, additional  
85 biomarkers are needed to ameliorate the diagnostic challenges of this extramedullary  
86 malignancy.

87  
88 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematopoietic disorder of  
89 plasmacytoid dendritic cells (17). BPDCN is a rare cancer, estimated to account for less than 1%  
90 of all hematologic malignancies, or roughly 700 cases annually in the United States (18, 19). In  
91 90% of patients, BPDCN presents with skin manifestations and is later accompanied by  
92 involvement of bone marrow, peripheral blood, and lymph nodes (20, 21). Progression to  
93 systemic disease is rapid, and median survival is estimated to be between 12 and 14 months  
94 (22). Diagnosis of BPDCN relies on clinical presentation, histological evaluation of the lesion,  
95 and immunophenotyping (23). Due to cutaneous involvement that presents with blast cells in  
96 the dermis, suspicion is often high for soft tissue tumors, T-cell leukemias/lymphomas, and NK-

97 cell leukemias/lymphomas (22). It can be difficult to differentiate these malignancies from  
98 BPDCN, and immunophenotyping is critical to validate the observed skin lesions are comprised  
99 of plasmacytoid dendritic cells rather than myeloid or lymphoid blasts (24). Additionally,  
100 expression of antigens expressed by other cell lineages, such as CD56 on NK/T-cell  
101 leukemia/lymphomas, and CD4 and CD123 on AMLs can make it difficult to render a definitive  
102 diagnosis (25). Thus, additional immunohistochemical markers in the diagnostic panel of BPDCN  
103 can help differentiate this malignancy from others with similar morphologic characteristics and  
104 clinical presentations.

105

106 We hypothesized that IRF8 may serve as a useful biomarker for myeloid sarcoma and BPDCN  
107 due to their prominent monoblastic and dendritic cell origin, respectively. Herein, we  
108 demonstrate that IRF8 is able to stain neoplastic cells of both myeloid sarcoma and BPDCN,  
109 even in cases lacking traditional markers for these malignancies. Importantly, IRF8 expression is  
110 absent in a panel of soft-tissue cancers that could potentially mimic myeloid sarcoma and  
111 BPDCN, as well as solid tumors. Our work demonstrates the utility for IRF8 in the identification  
112 of these rare hematologic malignancies that are in need of additional markers to aid in  
113 diagnosis.

114

## 115 **2.0: Methods**

### 116 2.1: Human Tumor Samples and TMA Creation

117 35 cases of myeloid sarcoma and 13 cases of BPDCN were obtained following approval by the  
118 Yale institutional review board. All cases were diagnosed by board-certified pathologists at the

119 Yale School of Medicine according to their WHO criteria and validated by a second reviewer at  
120 outside institutions. Both a pan-cancer tissue microarray of 150 cases spanning 25 tumor  
121 subtypes and 27 tissue-matched normal samples as well as a triple-negative breast cancer-  
122 specific TMA of 97 cases were made in the Department of Pathology at the Yale School of  
123 Medicine. All cases were previously diagnosed at Yale and utility of these biopsies in this study  
124 was approved by the Yale institutional review board. In addition, we used specimens from  
125 select sections of various previously published sarcoma-specific TMAs, including desmoplastic  
126 small round cell tumor (n=30), Ewing sarcoma (n=24), synovial sarcoma (n=45), and  
127 undifferentiated pleomorphic sarcoma (n=12).

128

## 129 2.2: IHC Staining and Scoring

130 Immunohistochemistry (IHC) of all aforementioned samples and TMAs was performed using a  
131 rabbit monoclonal IRF8 antibody (Anti-IRF8 ab207418 from Abcam, 1:900 dilution) as previously  
132 described (8). We additionally stained myeloid sarcoma samples with both myeloperoxidase  
133 (MPO rabbit polyclonal concentrate from Dako, 1:10 000 dilution) and CD34 (QBEND from  
134 Ventana, Neat), and BPDCN samples with CD123 (9F5 from BD Biosciences, 1:50 dilution). Cases  
135 that were double stained with IRF8 and lysozyme utilized the double-staining protocol on Bond  
136 with lysozyme (polyclonal from Agilent, Neat). To perform staining, formalin-fixed, paraffin-  
137 embedded tumor tissue sections were deparaffinized and rehydrated prior to antigen retrieval  
138 and primary antibody incubation. Afterward, specimens were incubated with diaminobenzidine  
139 (DAB) chromagen for primary antibody detection and counterstained with hematoxylin. All  
140 stained samples were evaluated for both percentage of immunoreactive cells and staining

141 intensity (0, negative; 1+, weak; 2+, moderate; 3+, strong) (26). When possible for both TMAs  
142 and whole tissue sections, at least 3 non-adjacent fields containing tumor cells were evaluated  
143 for IRF8 staining. Only IRF8 nuclear staining of neoplastic cells was considered positive, as  
144 several samples demonstrated cytoplasmic staining of cancerous cells or nuclear staining of  
145 infiltrating lymphocytes. Nuclear reactivity at any intensity was denoted as positive for IRF8 and  
146 given as percentage of overall tumor cells in a sample. Percentage of positive cells within tumor  
147 was also scored for CD34 and MPO in all myeloid sarcoma cases.

148

### 149 2.3: TCGA Database Analysis

150 Expression levels of IRF8 across different cancer types and their matched normal tissue were  
151 analyzed using Gene Expression Profiling Interactive Analysis (GEPIA), which utilizes global RNA-  
152 Seq data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx)  
153 databases. While TCGA contains expression data from 33 types of cancer, we collated this  
154 dataset to only analyze subtypes that were represented in our pan-cancer and sarcoma TMAs.  
155 We then determined the log<sub>2</sub> fold change of IRF8 expression between cancerous and normal  
156 tissue, utilizing a fold-change threshold of 1 and a p-value cutoff of 0.01 (as determined by a  
157 one-way ANOVA) to identify significantly different IRF8 transcript abundance between these  
158 two groups.

159

## 160 **3.0: Results**

### 161 3.1: IRF8 abundance is elevated in monocyte-derived myeloid sarcoma

162 In order to investigate IRF8 expression in tumors of monocytic origin, we evaluated its abundance

163 in myeloid sarcoma, an extramedullary malignancy of neoplastic immature monocytes and/or  
164 granulocytes (9). We performed immunohistochemical staining of 35 myeloid sarcoma patient  
165 samples and concomitantly stained for CD34, a hematopoietic stem cell marker, and  
166 myeloperoxidase (MPO), a myeloid marker. IRF8 was detectable in 24 of 35 (68.5%) of these  
167 cases, and CD34 was often undetectable in cases with the greatest degree of IRF8 positivity  
168 (Figure 1). Importantly, there were six cases for which IRF8 positivity was observed in the absence  
169 of CD34 or MPO expression, suggesting that IRF8 is able to identify myeloid sarcomas of primarily  
170 monocytic origin (Figure 2). In order to confirm monocytic origin of these blasts, double staining  
171 with lysozyme was performed on select MPO-negative specimens with sufficient remaining  
172 tissue. These showed blasts that were IRF8+ lysozyme+ as well as background scattered mature  
173 monocytes that were IRF8- lysozyme+ (Figure 3).

174

### 175 3.2: IRF8 is expressed in blastic plasmacytoid dendritic cell neoplasm

176 After observing IRF8 upregulation in myeloid sarcoma, we next investigated IRF8 abundance in  
177 blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy arising  
178 from immature plasmacytoid dendritic cells (17). Staining of 13 BPDCN cases demonstrated  
179 uniform IRF8 expression, with 13/13 (100%) samples showing positive IRF8 staining by  
180 immunohistochemistry. Importantly, there were multiple cases that stained negative for CD123,  
181 a marker commonly used in the diagnosis of BPDCN, but positive for IRF8 (Figure 4). This finding  
182 suggests that IRF8 holds promise as a marker for multiple difficult-to-diagnose hematologic  
183 malignancies of monocytic or dendritic cell origin.

184

185 3.3: Assessment of IRF8 expression across different cancer types

186 We next sought to evaluate IRF8 expression across additional tumor types and normal tissues in  
187 order to validate that presence of IRF8 is specific to hematopoietic malignancies. Consequently,  
188 we performed IRF8 staining of a pan-cancer TMA comprising 177 patient samples of both normal  
189 and cancerous tissue across 11 tissue types and 25 cancer subtypes. IRF8 expression was negative  
190 in all normal tissue samples and all but one tumor sample, which was a diffuse large B-cell  
191 lymphoma of the testis (Table 1, Figure 5). We also sought to further evaluate IRF8 expression in  
192 breast cancer, as our small cohort of breast cancers in the initial pan-cancer TMA were devoid of  
193 triple-negative breast cancers (TNBCs). We additionally assessed IRF8 expression on a TMA of 97  
194 TNBCs and observed that 2 (2.1%) of these tumors were IRF8-positive. The staining pattern for  
195 these cases was weak and showed subset reactivity (Figure 5). In many samples, we observed  
196 IRF8 staining of background lymphocytes that spared large, neoplastic cells.

197  
198 We next analyzed publicly available expression data from The Cancer Genome Atlas (TCGA) to  
199 further assess IRF8 expression between normal and cancerous tissues for malignancies included  
200 in the TMA. In line with previous reports, IRF8 was significantly upregulated in acute myeloid  
201 leukemia and diffuse large B-cell lymphoma samples relative to normal tissue (7). However, IRF8  
202 mRNA expression was also increased in colon adenocarcinoma, stomach adenocarcinoma, and  
203 testicular germ cell tumors (Figure 6). While these tumors were represented in our pan-cancer  
204 TMA, we did not observe a similar upregulation of IRF8 protein in the neoplastic cells, but rather  
205 in infiltrating lymphocytes (Table 1).

206

207 We next performed IRF8 staining on sarcoma TMAs of subtypes that may be considered in the  
208 differential diagnosis of myeloid sarcoma or BPDCN. IRF8 expression was not observed in any of  
209 the 111 soft-tissue tumors belonging to 4 subtypes of sarcomas in these TMAs, which included  
210 desmoplastic small round cell tumor, Ewing sarcoma, synovial sarcoma, and undifferentiated  
211 pleomorphic sarcoma (Table 2). These results indicate that IRF8 expression is specifically  
212 upregulated in monocyte-derived soft-tissue tumors and can be utilized to identify myeloid  
213 sarcomas that lack CD34 or MPO expression. Taken together, these findings suggest that  
214 increased abundance of IRF8 has the potential to distinguish malignant cells across several cancer  
215 types and is most significantly associated with hematologic malignancies.

216

#### 217 **4.0: Discussion**

218 Malignancies derived from monoblasts are often difficult to diagnose, owing to their occasional  
219 morphologic overlap with other malignancies as well as a dearth of reliable  
220 immunohistochemical stains for these early hematopoietic progenitors (27). We recently  
221 identified IRF8 as a sensitive and specific monoblast marker in cases of acute monocytic  
222 leukemia (AMoLs) by demonstrating its strong correlation with aspirate blast count in AMoLs  
223 (8). IRF8 is a transcription factor that upregulates genes critical for the differentiation of  
224 monocytes, dendritic cells, and macrophages (2). Prior work has demonstrated that IRF8  
225 expression peaks in monocyte and dendritic cell precursors, and thereafter remains high in  
226 mature dendritic cells but rapidly decreases in mature monocytes, suggesting it will potentially  
227 stain immature monocytic/dendritic cell populations (3, 28). Herein, we have demonstrated

228 that IRF8 is expressed in multiple hematologic malignancies of monoblastic/dendritic cell origin  
229 and holds promise as a biomarker for these difficult-to-diagnose neoplasms.

230

231 Given our recent work demonstrating IRF8 as a reliable monoblast marker, we sought to  
232 evaluate the utility of IRF8 in staining monocyte-derived hematopoietic cancers for which  
233 clinical diagnosis is challenging and helpful tissue markers are lacking. We first stained for IRF8  
234 in samples of myeloid sarcoma, an extramedullary tumor of mixed immature granulocyte and  
235 monocyte origin (15). Myeloid sarcoma can rarely occur as an isolated disease but is most  
236 commonly observed as a manifestation of acute myeloid leukemia, being reported in roughly  
237 2.5-9.1% of AML patients (11). It is often difficult for pathologists to diagnose, particularly in the  
238 absence of a previous AML diagnosis; prior studies have estimated that between 25-47% of  
239 myeloid sarcoma cases are misdiagnosed, largely due to inadequate immunophenotyping of  
240 the lesion (12-14). Consequently, we posited that IRF8 could be utilized to stain myeloid  
241 sarcoma cases with prominent monoblast populations. IRF8 was able to stain a significant  
242 proportion of myeloid sarcoma cases, including those negative for CD34 and MPO; these cases  
243 that had previous/concurrent marrows did indeed demonstrate monocytic differentiation by  
244 aspirate morphology with or without flow immunophenotypic support. Additionally, IRF8 did  
245 not stain any other soft-tissue tumors on sarcoma TMAs representing some of the differential  
246 diagnoses of myeloid sarcoma, including Ewing sarcoma, undifferentiated pleomorphic  
247 sarcoma, desmoplastic small round cell tumor and synovial sarcoma (29). Thus, IRF8 can be  
248 utilized as a biomarker for myeloid sarcoma and has the potential to improve diagnostic

249 accuracy of this less common hematologic malignancy, particularly for cases which are primarily  
250 of monocytic origin.

251  
252 We next evaluated the utility of IRF8 in staining malignant cells in blastic plasmacytoid dendritic  
253 cell neoplasm (BPDCN). BPDCN is an aggressive, rare tumor derived from precursors of  
254 plasmacytoid dendritic cells that often presents asymptotically or with multiple bruise-like  
255 cutaneous lesions before progressing to involve extracutaneous sites (20). In roughly 66% of  
256 patients, BPDCN presents as stage IV disease at time of diagnosis, and median survival is  
257 estimated to be between 12 and 14 months (22). BPDCN diagnosis is made on the basis of  
258 clinical features, morphological findings, and immunophenotype. Diagnosis is challenging, and  
259 BPDCN is often difficult to distinguish from soft-tissue tumors, AML, and T-cell  
260 leukemias/lymphomas. This is due to both an overlap in immunophenotyping as well as the  
261 common lymphoid-like morphology of BPDCN blasts that leads to a false suspicion of  
262 lymphoma (30). Given the dendritic cell lineage of BPDCN blasts and the diagnostic difficulties  
263 associated with the disease, we hypothesized that IRF8 could be a useful tool in staining  
264 neoplastic BPDCN cells. All 13 samples we obtained of this highly rare tumor were strongly  
265 positive for IRF8 staining. Additionally, several of these IRF8-positive cases were negative for  
266 CD123, a marker commonly used for BPDCN, suggesting that IRF8 may be a useful marker to  
267 add to the diagnostic panel for this aggressive hematopoietic malignancy (31).

268  
269 Following the identification of positive IRF8 staining in myeloid sarcoma and BPDCN, we sought  
270 to determine if its expression is specific to cancers of hematologic origin. We showed that IRF8

271 did not stain any solid tumors or normal tissue on a pan-cancer TMA comprising 25 cancer  
272 subtypes. However, global expression data from The Cancer Genome Atlas (TCGA) suggested  
273 that IRF8 is transcriptionally upregulated in several carcinomas relative to normal tissue,  
274 particularly colon adenocarcinoma, stomach adenocarcinoma, and testicular germ cell tumors,  
275 all of which were represented in our TMA. In contrast to this TCGA data, prior reports have  
276 indicated that IRF8 expression is preferentially decreased in both colon and gastric cancer  
277 samples relative to noncancerous tissue, through mechanisms such as increased promoter  
278 methylation (32, 33). This discrepancy highlights the discordance that can be observed between  
279 TCGA data and primary patient samples. Moreover, while breast cancers represented in the  
280 pan-cancer TMA were uniformly IRF8-negative, we performed additional staining on a TMA  
281 specific for triple-negative breast cancers (TNBCs) due to a recent study documenting increased  
282 IRF8 expression in estrogen receptor-negative breast cancers (34). However, only rare cases  
283 (2.1%) of the TNBCs in this TMA stained weakly positive for IRF8. This observation is potentially  
284 due to the fact that these investigators found IRF8 expression to be increased specifically in  
285 early-stage ER-negative cancers, which may not have been as well represented on the TMA as  
286 advanced disease. Importantly, and in line with recent work, IRF8 upregulation was most  
287 significantly associated with AML and diffuse large b-cell lymphoma in the TCGA dataset,  
288 further indicating that IRF8 likely has greatest utility as a marker of hematopoietic neoplasms  
289 (7).

290

291 In this study, we demonstrate that IRF8 can be used to identify monocyte and dendritic cell-  
292 derived malignancies that are prone to misdiagnosis due to a scarcity of specific markers. Our

293 study is limited by the relatively few cases of BPDCN. In addition, since B-cell lymphomas are  
294 also positive for IRF8, the marker does not help to differentiate among hematopoietic tumors.  
295 Further validation of these findings will be critical in order to integrate IRF8 staining into  
296 pathologists' workflow for diagnosis of these diseases. Additionally, future studies should build  
297 upon this work by determining if differential IRF8 expression correlates with poor prognosis or  
298 response to therapy in the diseases it stains. While this will likely prove challenging due to the  
299 rarity of both myeloid sarcoma and BPDCN, identifying additional prognostic markers for these  
300 diseases is crucial, particularly given the lack of data regarding survival differences between  
301 granulocyte-predominant and monocyte-predominant myeloid sarcoma (35). IRF8 thus may  
302 hold promise not only as a marker for diagnosis but also as a prognostic indicator that guides  
303 treatment intervention for these rare hematopoietic neoplasms.

304

### 305 **Acknowledgements**

306 We acknowledge Amos Brooks and Lori Charette from Yale Pathology Tissue Services for their  
307 invaluable experience and aid with immunohistochemical studies as well as tissue procurement  
308 and processing.

309

### 310 **Conflict of Interest**

311 The authors have disclosed that they have no significant relationships with, or financial interest  
312 in any commercial companies pertaining to this article.

313

### 314 **Ethics Approval and Consent to Participate**

315 The study was performed in accordance with the Declaration of Helsinki. The study was  
316 approved by an internal review board (local ethics committee HIC protocol #2000023891).

317

### 318 **Author Contributions**

319 D.C.M., S.G.K., and M.L.X. contributed equally in conception and design. D.C.M., M.L.X, and G.P.  
320 carried out data analysis. W.W. contributed additional cases. D.C.M. wrote the manuscript with  
321 significant contributions from M.L.X. and S.G.K. All authors edited the manuscript.

322

### 323 **Funding**

324 The authors have no funding sources to declare.

325

### 326 **Data Availability**

327 The tissue sections analyzed during this study are available from the corresponding author  
328 upon request. TCGA data analyzed during this study are publicly available using the [GEPIA](#)  
329 [online resource](#).

330

331

332

333

334

335

336

337 **References**

- 338 1. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K. ICSBP directs bipotential  
339 myeloid progenitor cells to differentiate into mature macrophages. *Immunity*. 2000;13(2):155-  
340 65.
- 341 2. Kurotaki D, Osato N, Nishiyama A, Yamamoto M, Ban T, Sato H, et al. Essential role of the  
342 IRF8-KLF4 transcription factor cascade in murine monocyte differentiation. *Blood*.  
343 2013;121(10):1839-49.
- 344 3. Kurotaki D, Yamamoto M, Nishiyama A, Uno K, Ban T, Ichino M, et al. IRF8 inhibits C/EBP $\alpha$   
345 activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils.  
346 *Nat Commun*. 2014;5:4978.
- 347 4. Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN  
348 regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells.  
349 *J Immunol*. 2003;170(3):1131-5.
- 350 5. Yamamoto M, Kato T, Hotta C, Nishiyama A, Kurotaki D, Yoshinari M, et al. Shared and  
351 distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development. *PLoS*  
352 *One*. 2011;6(10):e25812.
- 353 6. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8  
354 mutations and human dendritic-cell immunodeficiency. *N Engl J Med*. 2011;365(2):127-38.
- 355 7. Liss F, Frech M, Wang Y, Giel G, Fischer S, Simon C, et al. IRF8 Is an AML-Specific Susceptibility  
356 Factor That Regulates Signaling Pathways and Proliferation of AML Cells. *Cancers (Basel)*.  
357 2021;13(4).

- 358 8. Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic  
359 Leukemias. *Am J Surg Pathol*. 2021;45(10):1391-8.
- 360 9. Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, et al. Myeloid sarcomas: a  
361 histologic, immunohistochemical, and cytogenetic study. *Diagn Pathol*. 2007;2:42.
- 362 10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008  
363 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute  
364 leukemia: rationale and important changes. *Blood*. 2009;114(5):937-51.
- 365 11. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid  
366 leukemia. *Blood*. 2011;118(14):3785-93.
- 367 12. Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid Sarcoma:  
368 Presentation, Diagnosis, and Treatment. *Clin Lymphoma Myeloma Leuk*. 2017;17(5):263-7.
- 369 13. Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, et al. Is there a "gold"  
370 standard treatment for patients with isolated myeloid sarcoma? *Biomed Pharmacother*.  
371 2013;67(1):72-7.
- 372 14. Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma:  
373 report of two cases and a review of 72 cases in the literature. *Cancer*. 2002;94(6):1739-46.
- 374 15. Magdy M, Abdel Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M. Myeloid  
375 Sarcoma. *Oncol Res Treat*. 2019;42(4):224-9.
- 376 16. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-  
377 pathologic, phenotypic and cytogenetic analysis of 92 adult patients. *Leukemia*. 2007;21(2):340-  
378 50.

- 379 17. Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, et al. Molecular  
380 profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests  
381 selective sensitivity to NF-kB pathway inhibition. *Leukemia*. 2014;28(8):1606-16.
- 382 18. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and  
383 characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. *Haematologica*. 2004;89(1):58-  
384 69.
- 385 19. Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic  
386 plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.  
387 *Haematologica*. 2013;98(2):239-46.
- 388 20. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of  
389 blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series  
390 of 33 patients. *Am J Surg Pathol*. 2010;34(1):75-87.
- 391 21. Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, et al. Blastic plasmacytoid  
392 dendritic cell neoplasm: clinical features in 90 patients. *Br J Dermatol*. 2013;169(3):579-86.
- 393 22. Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. *Arch*  
394 *Pathol Lab Med*. 2014;138(4):564-9.
- 395 23. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm.  
396 *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):16-23.
- 397 24. Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, et al. Blastic plasmacytoid  
398 dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and  
399 HyperCVAD therapy. *Am J Hematol*. 2016;91(3):283-6.

- 400 25. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al. Extended  
401 diagnostic criteria for plasmacytoid dendritic cell leukaemia. *Br J Haematol.* 2009;145(5):624-  
402 36.
- 403 26. Parris TZ, Aziz L, Kovács A, Hajizadeh S, Nemes S, Semaan M, et al. Clinical relevance of  
404 breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma. *BMC*  
405 *Cancer.* 2014;14:324.
- 406 27. Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ. Morphological  
407 evaluation of monocytes and their precursors. *Haematologica.* 2009;94(7):994-7.
- 408 28. Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, et al. IRF8  
409 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional  
410 and Plasmacytoid Dendritic Cells, Respectively. *Immunity.* 2016;45(3):626-40.
- 411 29. Marwah N, Bhutani N, Budhwar A, Sen R. Isolated myeloid sarcoma of the temporal bone:  
412 As the first clinical manifestation of acute myeloid leukemia in a patient of down's syndrome.  
413 *Int J Surg Case Rep.* 2019;58:77-80.
- 414 30. Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, et al. How should we  
415 diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? *Blood Adv.*  
416 2019;3(24):4238-51.
- 417 31. Laribi K, Denizon N, Besançon A, Farhi J, Lemaire P, Sandrini J, et al. Blastic Plasmacytoid  
418 Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. *Biol Blood Marrow*  
419 *Transplant.* 2016;22(8):1357-67.

- 420 32. Ibrahim MLL, K. IRF8 deficiency in colonic epithelial cells promotes inflammation-mediated  
421 colon tumorigenesis and myeloid-derived suppressor cell differentiation. *J Immunol.*  
422 2017;198(66.20).
- 423 33. Yamashita M, Toyota M, Suzuki H, Nojima M, Yamamoto E, Kamimae S, et al. DNA  
424 methylation of interferon regulatory factors in gastric cancer and noncancerous gastric  
425 mucosae. *Cancer Sci.* 2010;101(7):1708-16.
- 426 34. Gatti G, Betts C, Rocha D, Nicola M, Grupe V, Ditada C, et al. High IRF8 expression correlates  
427 with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative  
428 breast cancer. *Breast Cancer Res.* 2021;23(1):40.
- 429 35. Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options.  
430 *Ther Adv Hematol.* 2011;2(5):309-16.
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441

442 **Figure/table legends**

443 **Figure 1: IRF8 expression in myeloid sarcoma.** Heat map of myeloid sarcoma cases based on  
444 percent positivity of tumor cells for IRF8, CD34, or MPO by immunohistochemistry.

445  
446 **Figure 2: Representative case of myeloid sarcoma at 2X, 20X magnification.** This tumor shows  
447 strong IRF8 expression in the monoblastic population of tumor cells and MPO staining in the  
448 granulocytic population (Case 8 in Figure 1). IRF8 expression is dimly observed in the mantle  
449 zone B cells adjacent to neoplastic cells.

450  
451 **Figure 3: IRF8 and lysozyme staining in monocytic malignancies.** Double stain with IRF8  
452 (brown) and lysozyme (red) highlights double-positive monoblasts in a case of myeloid sarcoma  
453 (Case 1) and lysozyme single-positive monocytes in the skin (Case 2).

454  
455 **Figure 4: Expression patterns of BPDCN in three representative patients.** Case 1 shows a mid-  
456 chest skin biopsy. Case 2 shows a bone marrow biopsy. Case 3 shows a left chest skin biopsy. All  
457 images taken at 200x magnification.

458  
459 **Figure 5: Representative cases of IRF8 immunohistochemistry from pan-cancer TMA.** Case 1  
460 shows a squamous cell skin carcinoma with IRF8 staining of infiltrating lymphocytes but not  
461 neoplastic cells. Case 2 shows a gastric adenocarcinoma with a similar staining pattern to Case  
462 1. Case 3 shows a testicular lymphoma with IRF8 staining of large, polymorphic tumor cells.  
463 Case 4 shows a representative case of an IR8-positive TNBC.

464

465 **Figure 6: IRF8 expression in cancerous tissues (red) and normal tissues (gray).** Box plots

466 marked with a red asterisk indicate a statistically significant difference ( $p < .05$ ) between tumor

467 and normal tissue. BLCA – Bladder Urothelial Carcinoma, BRCA – Breast Invasive Carcinoma,

468 COAD – Colon Adenocarcinoma, DLBC – Lymphoid Neoplasm Diffuse Large B-Cell Lymphoma,

469 KIRP – Kidney Renal Papillary Cell Carcinoma, LAML – Acute Myeloid Leukemia, LIHC – Liver

470 Hepatocellular Carcinoma, LUAD – Lung Adenocarcinoma, LUSC – Lung Squamous Cell

471 Carcinoma, OV – Ovarian Serous Cystadenocarcinoma, SARC – Sarcoma,

472 STAD – Stomach Adenocarcinoma, TGCT – Testicular Germ Cell Tumors.

473

474 **Table 1: IRF8 expression in normal tissues and malignancies of different origins included in a**

475 pan-cancer TMA.

<b>Tissue</b>	<b>Subtype</b>	<b>Negative</b>	<b>Positive</b>	<b>Total</b>
Bladder	Normal Bladder	3 (100%)	0	3
	Papillary Transitional Cell Carcinoma	1 (100%)	0	1
	Papillary Urothelial Carcinoma	4 (100%)	0	4
	Serous Adenocarcinoma	1 (100%)	0	1
	Urothelial Carcinoma	10 (100%)	0	10
Breast	Ductal Carcinoma	9 (100%)	0	9
	Lobular Carcinoma	1 (100%)	0	1
Colon	Normal Colon	2 (100%)	0	2
	Adenocarcinoma	13 (100%)	0	13
Kidney	Normal Kidney	3 (100%)	0	3
	Papillary Renal Cell Carcinoma	10 (100%)	0	10
	Renal Cell Carcinoma	4 (100%)	0	4
Liver	Normal Liver	4 (100%)	0	4
	Hepatocellular Carcinoma	14 (100%)	0	14
	Mixed Hepatocholangiocarcinoma	1 (100%)	0	1
Lung	Normal Lung	2 (100%)	0	2
	Adenocarcinoma	7 (100%)	0	7


	Neuroendocrine Carcinoma	1 (100%)	0	1
	Squamous Cell Carcinoma	8 (100%)	0	8
Ovary	Normal Ovary	4 (100%)	0	4
	Adenocarcinoma	12 (100%)	0	12
Pancreas	Normal Pancreas	3 (100%)	0	3
	Adenocarcinoma	1 (100%)	0	1
	Endocrine Carcinoma	12 (100%)	0	12
	Neuroendocrine Carcinoma	2 (100%)	0	2
Skin	Normal Skin	2 (100%)	0	2
	Squamous Cell Carcinoma	14 (100%)	0	14
Stomach	Normal Stomach	2 (100%)	0	2
	Adenocarcinoma	10 (100%)	0	10
Testis	Normal Testis	2 (100%)	0	2
	Embryonal Carcinoma	1 (100%)	0	1
	Leydig Cell Carcinoma	2 (100%)	0	2
	Lymphoma	0	1 (100%)	1
	Mixed Germ Cell Carcinoma	6 (100%)	0	6
	Seminoma	5 (100%)	0	5

476

477 **Table 2:** IRF8 expression in different types of sarcoma included in sarcoma-specific TMAs.

<b>Sarcoma Type</b>	<b>Negative</b>	<b>Positive</b>	<b>Total</b>
Desmoplastic small round cell tumor	30 (100%)	0	30
Ewing sarcoma	24 (100%)	0	24
Synovial sarcoma	45 (100%)	0	45
Undifferentiated pleomorphic sarcoma	12 (100%)	0	12


478

**IRF8****CD34****MPO**

2X



20X

H&E





medRxiv preprint doi: <https://doi.org/10.1101/2021.12.06.21267361>; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


MPO




IRF8



**CASE 1**



**CASE 2**






H&E

CD123




IRF8

CASE 1






medRxiv preprint doi: <https://doi.org/10.1101/2021.12.06.21267361>; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CASE 2





CASE 3





**H&E**

**IRF8**

**CASE 1**





**CASE 2**



medRxiv preprint doi: <https://doi.org/10.1101/2021.12.06.21267361>; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**CASE 3**



**CASE 4**

